Superworth

Adma Biologics price to free cash flow ADMA

Market value divided by free cash flow over the last twelve months, since 2024.

Today, Nov 2, 2026
21.3×
3-year median
56.7×
Against its 3-year history
18th
percentile: 0 is its lowest day, 100 its highest
3-year range
17.1× to 386×
Peer median
30.2×

Adma Biologics' price to free cash flow is 21.3× as of Nov 2, 2026.

That is below its 3-year median of 56.7×, lower than on 82% of days in the last 3 years.

Over that time it ranged from 17.1× in Jun 2026 to 386× in May 2024.

The median for 10 biotech stocks of a similar size is 30.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far21.3×17.1×133×
2025113×38.7×116×
202452.0×51.8×386×

Against its peers

Companies in Biotechnology nearest Adma Biologics' size, closest first, today.

CompanyPrice to free cash flow
ADMAAdma Biologics21.3×
VCELVericel33.6×
MGTXMeiraGTx85.5×
KRYSKrystal Biotech34.0×
RGENRepligen87.2×
TECHBIO-TECHNE43.3×
HALOHalozyme Therapeutics18.2×
NBIXNeurocrine Biosciences17.0×
EXELExelixis14.8×
ALNYAlnylam Pharmaceuticals26.7×
INCYIncyte12.7×
Peer median30.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Adma Biologics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.